CN108883122A - 有用于治疗疾病的c-糖苷化合物 - Google Patents

有用于治疗疾病的c-糖苷化合物 Download PDF

Info

Publication number
CN108883122A
CN108883122A CN201780020502.2A CN201780020502A CN108883122A CN 108883122 A CN108883122 A CN 108883122A CN 201780020502 A CN201780020502 A CN 201780020502A CN 108883122 A CN108883122 A CN 108883122A
Authority
CN
China
Prior art keywords
methyl
tetrahydro
pyran
hydroxymethyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780020502.2A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·W·简特卡
劳雷尔·麦多克-麦克格雷恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fimbrion Therapeutics Inc
Original Assignee
Fimbrion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fimbrion Therapeutics Inc filed Critical Fimbrion Therapeutics Inc
Publication of CN108883122A publication Critical patent/CN108883122A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201780020502.2A 2016-03-11 2017-03-11 有用于治疗疾病的c-糖苷化合物 Pending CN108883122A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662307078P 2016-03-11 2016-03-11
US62/307,078 2016-03-11
PCT/US2017/021983 WO2017156508A1 (en) 2016-03-11 2017-03-11 C-glycoside compounds useful for treating disease

Publications (1)

Publication Number Publication Date
CN108883122A true CN108883122A (zh) 2018-11-23

Family

ID=59789872

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780020502.2A Pending CN108883122A (zh) 2016-03-11 2017-03-11 有用于治疗疾病的c-糖苷化合物

Country Status (5)

Country Link
US (1) US20200002303A1 (enExample)
EP (1) EP3426260A4 (enExample)
JP (1) JP2019508504A (enExample)
CN (1) CN108883122A (enExample)
WO (1) WO2017156508A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021197363A1 (zh) * 2020-03-31 2021-10-07 苏州大学 2-炔基甘露糖衍生物及其应用
CN113795487A (zh) * 2019-05-07 2021-12-14 葛兰素史密斯克莱知识产权发展有限公司 新的化合物
CN115197185A (zh) * 2021-04-12 2022-10-18 中国科学院大连化学物理研究所 一种过渡金属催化的吡喃糖苷衍生物的制备方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018069147A2 (pt) 2016-03-23 2019-01-22 Fimbrion Therapeutics Inc composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh
PL3820856T3 (pl) * 2018-07-10 2022-12-19 Glaxosmithkline Intellectual Property Development Limited Związki c-mannozydów przydatne w leczeniu zakażeń układu moczowego
US12351597B2 (en) 2019-06-19 2025-07-08 Glaxosmithkline Intellectual Property Development Limited Substituted biphenyl or phenylheteroaryl-mannosides as antagonists of FimH
CN114585359B (zh) * 2019-10-16 2025-08-12 凯莫森特里克斯股份有限公司 用于治疗pd-l1疾病的杂芳基联苯酰胺
CN113582956A (zh) * 2020-04-30 2021-11-02 华东师范大学 含硫芳基碳苷类化合物及其合成方法和应用
CN115656356B (zh) * 2022-09-30 2025-03-21 南京正济医药研究有限公司 4-羟基-7-苯氧基异喹啉-3-甲酸甲酯及其有关物质的测定方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014194270A1 (en) * 2013-05-30 2014-12-04 Washington University Compounds and methods for treating bacterial infections
US20150197536A1 (en) * 2012-07-28 2015-07-16 The Regents Of The University Of Colorado, A Body Corporate Compounds reducing the production of sorbitol in the eye and methods of using the same
CN105164142A (zh) * 2013-03-12 2015-12-16 沃泰克斯药物股份有限公司 用于治疗细菌感染的甘露糖衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2732311T3 (es) * 2011-02-07 2019-11-21 Univ Washington Compuestos de manósidos y procedimientos de uso de los mismos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150197536A1 (en) * 2012-07-28 2015-07-16 The Regents Of The University Of Colorado, A Body Corporate Compounds reducing the production of sorbitol in the eye and methods of using the same
CN105164142A (zh) * 2013-03-12 2015-12-16 沃泰克斯药物股份有限公司 用于治疗细菌感染的甘露糖衍生物
WO2014194270A1 (en) * 2013-05-30 2014-12-04 Washington University Compounds and methods for treating bacterial infections

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113795487A (zh) * 2019-05-07 2021-12-14 葛兰素史密斯克莱知识产权发展有限公司 新的化合物
WO2021197363A1 (zh) * 2020-03-31 2021-10-07 苏州大学 2-炔基甘露糖衍生物及其应用
US11964996B2 (en) 2020-03-31 2024-04-23 Jiyue Zheng 2-alkynylmannose derivative and application thereof
CN115197185A (zh) * 2021-04-12 2022-10-18 中国科学院大连化学物理研究所 一种过渡金属催化的吡喃糖苷衍生物的制备方法
CN115197185B (zh) * 2021-04-12 2024-03-22 中国科学院大连化学物理研究所 一种过渡金属催化的吡喃糖苷衍生物的制备方法

Also Published As

Publication number Publication date
US20200002303A1 (en) 2020-01-02
WO2017156508A1 (en) 2017-09-14
EP3426260A4 (en) 2019-08-14
JP2019508504A (ja) 2019-03-28
EP3426260A1 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
US20220235087A1 (en) Mannose-derived antagonists of fimh useful for treating disease
CN108883122A (zh) 有用于治疗疾病的c-糖苷化合物
CA3124898C (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
US20250009723A1 (en) Mannose-derived antagonists of fimh useful for treating disease
AU2013334236B2 (en) Heteroaryl inhibitors of PDE4
CA2876690C (en) Dihydropyrimidine compounds and their application in pharmaceuticals
TW202313593A (zh) 作為鈉通道調節劑之ｎ—（羥基烷基（雜）芳基）四氫呋喃甲醯胺
CN114430743A (zh) 甲状腺激素受体β激动剂化合物
CN101790527A (zh) Rho激酶的苯并噻吩抑制剂
BR112015014458B1 (pt) Compostos derivados de manose, seus intermediários, composição, uso e processos de preparação
JP2022535577A (ja) 癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体
CA3120514A1 (en) Cyclic ureas
AU2021225921A1 (en) Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease
TW202140499A (zh) 巨環ｒｉｐ２－激酶抑制劑
AU2016314355A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
KR20010034699A (ko) 3',3'-ｎ-비스-치환된 마크롤리드 ｌｈｒｈ 길항제
JP7721167B2 (ja) 新規な選択的ｆｌｔ３阻害剤としての１ｈ－イミダゾ［４，５－ｈ］キナゾリン化合物
JP7628506B2 (ja) 新規化合物
JP2025518041A (ja) ヘテロ環のｐａｄ４阻害剤
HK1163109A1 (en) Bicyclic derivatives of morphine-6-glucuronide, process for their preparation and their application in therapy
HK1163109B (en) Bicyclic derivatives of morphine-6-glucuronide, process for their preparation and their application in therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181123

WD01 Invention patent application deemed withdrawn after publication